Physician profile
Humera S Syeda
NPI 1538232897
$2,917.61
in general payments reported to CMS, 2019-2025
24 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $298 · 2021: $543 · 2022: $639 · 2023: $536 · 2024: $428 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.63 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Avion Pharmaceuticals | $344.14 | 2019-2021 | |
| Novo Nordisk INC | $247.69 | 2021-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $208.21 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $201.42 | 2019-2023 | Mara Console, Paragard T 380a |
| Mayne Pharma Commercial LLC | $128.33 | 2021-2023 | |
| Therapeuticsmd, INC. | $106.15 | 2019-2022 | |
| Astellas Pharma US INC | $99.84 | 2020-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $96.92 | 2019-2024 | Aptima |
| Exeltis, USA INC. | $93.79 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $90.89 | 2022 | |
| Pfizer INC. | $66.51 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $58.90 | 2019-2024 | Gardasil 9, Gardasil |
| Shield Therapeutics INC | $52.93 | 2024-2025 | |
| Organon LLC | $42.94 | 2022-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.71 | 2019-2025 | |
| Agile Therapeutics, INC. | $27.97 | 2021-2022 | |
| Ethicon US, LLC | $21.62 | 2022 | |
| Lilly USA, LLC | $20.36 | 2024 | Zepbound |
| Covidien LP | $17.40 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.76 | 2021 | |
| Lupin INC. | $15.70 | 2019 | |
| Millicent US INC | $14.02 | 2019 | |
| Allergan, INC. | $13.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humera Syeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.